The new and improved products are derived from novel
proprietary cannabis varieties developed using genetic markers
utilizing Evogene's GeneRator AI tech-engine
REHOVOT, Israel, Sept. 21,
2022 /PRNewswire/ -- Canonic Ltd., focused on the
development of medical grade cannabis products and a wholly owned
subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), today
announced the launch of its second-generation products in
Israel. The design of the new
products leverages market feedback since Canonic's launch of its
first-generation products in Israel in September
2021. The first new product from the second-generation
product-line is expected to debut for patients in early
October 2022. The rest of the
second-generation product line will follow during the last quarter
of the year through the first quarter of 2023.
Canonic's second-generation products are characterized by high
THC and unique terpene profiles. THC is the primary psychoactive
ingredient in cannabis. Terpenes are plant compounds known to have
complementary medicinal benefits, including anti-inflammatory,
analgesia, anxiolytic, antidepressant, anti-insomnia and more[1].
They also influence aroma and scent of the cannabis
inflorescence.
The new products were developed through breeding programs
carried out by Canonic in the last two years and include the
use of proprietary sets of novel genetic markers developed in
collaboration with Evogene using its GeneRator AI
tech-engine. The use of genetic markers directs and
accelerates the breeding process in reaching unique cannabis
lines that meet market requirements.
Arnon Heyman, Chief Executive
Officer of Canonic, commented, "We are happy to have reached
this milestone, representing the fruits of our development work
over past years. We have succeeded in increasing the cannabinoid
and terpene concentration, known to relieve many symptoms and
improve overall well-being, meeting patient demands within a
concise timeframe. This was enabled using advanced computational
technology, in combination with proprietary sets of novel genetic
markers and other advanced breeding methods, developed by Canonic
and Evogene. In addition, the announcement we published last week
regarding the licensing agreement for the commercialization in
Europe of two next-generation
cannabis lines by GroVida, is supporting proof of the uniqueness
and commercial potential of the new generation of products
developed by Canonic."
About Canonic Ltd.:
Canonic is a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE:
EVGN), developing medical cannabis products utilizing Evogene's
proprietary GeneRator AI engine. The Company's development
products aim to improve active compounds, genetic stability, and
cannabis varieties for specific medical effects. In addition,
the Company's strategy includes the development of cannabis
varieties to commercialize medical cannabis products independently
or through collaborations. Canonic has exclusive access to
Evogene's genomic assets and technology for the development of
medical cannabis products.
For more information, please
visit: https://www.canonicbio.com/.
About Evogene Ltd.:
Evogene (Nasdaq: EVGN, TASE: EVGN) is a computational biology
company aiming to revolutionize the development of life-science
based products by utilizing cutting edge technologies to increase
the probability of success while reducing development time and
cost. Evogene established three unique technological engines -
MicroBoost AI, ChemPass AI, and GeneRator AI – leveraging
Big Data and Artificial Intelligence and incorporating a deep
multidisciplinary understanding of life sciences. Each
technological engine is focused on the discovery and development of
products based on one of the following core components: microbes
(MicroBoost AI), small molecules (ChemPass AI), and
genetic elements (GeneRator AI). Evogene uses its
technological engines to develop products through subsidiaries and
strategic partners. Evogene's main subsidiaries currently
utilize the technological engines to develop human microbiome-based
therapeutics by Biomica Ltd., medical cannabis products by Canonic
Ltd., ag-chemicals by AgPlenus Ltd., and ag-biologicals by Lavie
Bio Ltd.
For more information, please visit:
www.evogene.com.
Forward Looking Statements:
This press release contains "forward-looking statements"
relating to future events. These statements may be identified by
words such as "may", "could", "expects", "intends", "anticipates",
"plans", "believes", "scheduled", "estimates", "demonstrates", or
words of similar meaning. For example, Evogene and Canonic are
using forward-looking statements in this press release when they
discuss the characteristics of the new second-generation products,
their unique qualities and their possible benefits for relieving
symptoms and improve overall well-being, and their expected
marketing date. Such statements are based on current expectations,
estimates, projections and assumptions, describe opinions about
future events, and involve certain risks and uncertainties which
are difficult to predict and are not guarantees of future
performance. Therefore, actual future results, performance or
achievements of Evogene and its subsidiaries may differ materially
from what is expressed or implied by such forward-looking
statements due to a variety of factors, many of which are beyond
the control of Evogene and its subsidiaries, including, without
limitation, those risk factors contained in Evogene's reports filed
with applicable securities authorities. Evogene and its
subsidiaries disclaim any obligation or commitment to update these
forward-looking statements to reflect future events or developments
or changes in expectations, estimates, projections and
assumptions.
Evogene Investor Contact:
Kenny Green
Email: kenny.green@evogene.com
Tel: +1 212 378 8040
Logo:
https://mma.prnewswire.com/media/1605436/Canonic_Logo.jpg
Logo: https://mma.prnewswire.com/media/890385/Evogene_Logo.jpg
[1]
http://accurateclinic.com/wp-content/uploads/2020/05/Medicinal-Properties-of-Cannabinoids-Terpenes-and-Flavonoids-in-Cannabis-and-Benefits-in-Migraine-Headache-and-Pain-An-Update-on-Current-Evidence-and-Cannabis-Science-2018.pdf
View original
content:https://www.prnewswire.com/news-releases/canonic-launches-its-second-generation-medical-cannabis-products-with-high-thc-and-unique-terpene-profiles-301629434.html
SOURCE Canonic